Etid klinik pou BPCO nan Oklahoma
8 etid pou BPCO ap chèche patisipan nan sit nan Oklahoma.
Vil nan Oklahoma
Tèks ofisyèl etid la (Anglè)
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- Epic Medical Research - Chickasha- Site Number : 8400097, Chickasha
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07190209Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- Layrek Clinical Research- Site Number : 8400066, Tulsa
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07190222A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Research Site, Oklahoma City
- Research Site, Tulsa
Ap rekriteFaz 2
Laj 40 ak plis · Tout sèks · Mizajou Sep 9, 2026 · NCT07082738A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
- Research Site, Oklahoma City
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06883305A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
- Research Site, Oklahoma City
- Research Site, Tulsa
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT06878261A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
- Research Site, Norman
- Research Site, Oklahoma City
- Research Site, Tulsa
Ap rekriteFaz 3
Laj 40 a 80 · Tout sèks · Mizajou Aug 26, 2026 · NCT06283966eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
- GSK Investigational Site, Edmond
Ap rekriteFaz 3
Laj 40 a 75 · Tout sèks · Mizajou Jul 28, 2026 · NCT07177339Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
- Hightower Clinical, Oklahoma City
Ap rekriteEtid obsèvasyon
Laj 50 ak plis · Tout sèks · Mizajou Aug 5, 2025 · NCT06122077Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.